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Abstract: Chemsex, a new risky sexual behavior involving participation in sexual relations under
the influence of drugs, has shown a significantly increased prevalence in recent years. This fact
entails a serious public health issue, especially when Chemsex is practiced by individuals with an
HIV (Human Immunodeficiency Virus) diagnosis. Hence, analyzing the characteristics of Chemsex
practices, associated sexual practices and the health outcomes of individuals who participate in
Chemsex, is extremely important. The main aim of the present study is to analyze the prevalence and
characteristics of the practice of Chemsex in a sample of 101 men with HIV who have sex with men
who attended the Department of Infectious Diseases of the General University Hospital of Alicante
(Spain). Furthermore, the association between Chemsex and Health-Related Quality of Life (HRQoL)
was also assessed. Chemsex and sexual practices were evaluated by employing a questionnaire
applied on an ad hoc basis. HRQoL was assessed by employing the Medical Outcomes Study HIV
Health Survey (MOS-HIV). In total, 40.6% of the participants had practiced Chemsex during the
last year. When sexual practices were compared between those individuals who practiced Chemsex
and those who did not, the former presented a higher level of risky sexual behaviors, especially
with occasional and multiple sexual partners. Regarding HRQoL, those individuals who practiced
Chemsex exhibited a poorer HRQoL in the majority of domains, especially those participants who
practiced it with a higher intensity. The present study points out the high prevalence of Chemsex
practice between men with HIV who have sex with men in Spain. Moreover, this study highlights the
negative effects of Chemsex on HRQoL, probably due to the mixed effects of higher levels of risky
sexual practices and the consequences of drug consumption.
Keywords: Chemsex; HIV; men who have sex with men; health-related quality of life
1. Introduction
Prevalence of HIV infection is a global public health issue—it is estimated that 1.7
million people were infected in 2018 alone [1]. In Spain, according to the annual report
on the epidemiology of HIV, issued by the Ministry of Health, during 2018, 3244 new
HIV diagnoses were reported, of which 85.3% were men. Of that percentage, 56.4%
corresponded to men who have sex with men (MSM), an epidemiological term used to
describe men who have sex with other men regardless of their sexual orientation or gender
identity [2]. This trend in the data remains consistent among other Western countries [3]
and represents a 19-fold increase in the probability of HIV infection [4].
These data confirm that HIV infection continues to be a highly prevalent public health
concern, especially in the MSM population [5]. Although new strategies such as pre-
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exposure prophylaxis (PReP) have emerged [6,7], prevention through condoms remains the
most recommended method due to its accessibility and effectiveness [8,9]. However, the
lack of condom use as a prophylactic method against HIV has contributed to an increase in
the transmission of HIV and other sexually transmitted diseases (STDs), such as syphilis,
gonorrhea, hepatitis, urethritis, genital warts and chlamydia in this population [10].
Beyond the classical prophylactic methods, the availability of effective antiretroviral
treatments has allowed people with HIV that have achieved and maintained an unde-
tectable viral load not to sexually transmit the virus to others [11,12]. This fact, although it
has allowed for great advances and a reduction in HIV transmission, has developed a false
sense of security in people living with HIV (PLWHIV), leading to a significant decrease
in the employment of prophylactic measures in their sexual relationships, resulting in
increased risky sexual behaviors and transmission of other STDs [13–15].
Although it is known that the previously explained phenomena could be the basis
for the risk of transmission of HIV and other STDs in PLWHIV, in recent years, it has
become clear that there is a need to identify other risky sexual behaviors that lead to a high
probability of transmission of the virus. However, most studies focused on promoting the
use of condoms and identifying the factors promoting their use, as shown in the review
conducted by Evans [16]. Nevertheless, there is little research on newer sexual phenomena
such as Chemsex. This term refers to the development of risky sexual relations under the
effects of drug use, with different purposes, such as increasing pleasure or prolonging the
duration of sexual intercourse [17–19]. This type of risky sexual behavior, which is highly
prevalent among MSM, in which substance use is mixed with the absence of prophylactic
measures, carries a high risk of contagion, and therefore is extremely serious, not only
because of the risk it poses to the individual himself, but to public health in general [20].
Drugs frequently used to increase sexual experiences include methamphetamine, crystal
meth, mephedrone, and gamma-hydroxybutyrate (GHB) [20–23]. Although the prevalence
of Chemsex is difficult to estimate because few individuals report the practice of such
behaviors [23,24], previous studies estimate that about 30–45% of MSM have practiced
Chemsex on at least one occasion [18,22,25]. This is why the identification of explanatory
variables of these types of phenomena and their relationship with both the physical and
psychological health of people is a challenge that should be taken up urgently by the
scientific community. In spite of this, information on this subject is scarce, partly due to the
novelty of the phenomenon and the difficulty in evaluating it.
Beyond the consequences of the practice of Chemsex increasing the risk of transmission
of HIV and other STDs, it is important to know the consequences of this risky sexual practice
on the health of the individuals who practice it. To the best of our knowledge, no previous
studies have identified the effects of Chemsex on specific health markers, such as Health-
Related Quality of Life (HRQoL). HRQoL is defined as a subjective outcome measure
that assesses the influence of health status and physical, mental, and social functioning in
relation to an individual’s goals [26–28] and is considered a measure of health outcomes
and treatment adherence among people with HIV [29]. Although, as has been indicated, no
previous studies have analyzed the relationship between Chemsex and HRQoL in men with
HIV who have sex with men, it has been demonstrated that there is a negative association
between some risky sexual behaviors, such as unprotected anal penetration and HRQoL
in this population [30–32]. There are some emerging mechanisms in the recent literature
that could help to explain the possible negative effects of Chemsex on the health of this
population. In this sense, the practice of Chemsex is associated with a decreased treatment
adherence in PLWHIV, limiting the effects of such treatments [33,34]. On the other hand,
a review conducted by Degroote, Vogelaers, and Vandijck [35] associated drug use with
poorer physical and mental health, finding that 25% of MSM with HIV who consume
drugs reported negative effects on their lives [36], a decrease in their autonomy in activities
of daily living [37], and a negative impact on their social and work relationships [38,39].
Mental health is also negatively affected among HIV-positive MSM who practice Chemsex,
with 15% of MSM experiencing a negative impact on their mental health [40–43]. It is likely
J. Clin. Med. 2021, 10, 1662 3 of 16
that the mixed effects of higher risky sexual practices and drug consumption consequences
could be the basis of the health deterioration of this population. However, more studies are
needed to characterize Chemsex practices and their consequences for HRQOL in men with
HIV who have sex with men.
With all this in mind, the main aim of the present study was to characterize the
phenomenon of Chemsex among a sample of Spanish men with HIV infection who have
sex with men, and to analyze the relationship between Chemsex and HRQoL in this
population.
2. Materials and Methods
2.1. Study Design and Participants
In this cross-sectional observational study, we included 101 men with HIV infection
who have sex with men. The majority of them had undertaken advanced studies, were
single, employed, with a mean economic income above 1500 euros per month, and self-
identified as homosexuals. The characteristics of the participants are summarized in
Table 1.
Table 1. Sociodemographic and serological status of the participants.
n = 101


















<EUR 1000 19 (18.8%)
EUR 1001–1500 20 (19.8%)
EUR 1501–2000 23 (22.8%)
EUR 2001–2500 16 (15.8%)






Time since HIV diagnosis (years) 9.37 ± 6.13
Current CD4+ lymphocytes (cells/µL.) 812.22 ± 307.33
Nadir CD4+ lymphocyte (cells/µL.) 469.28 ± 233.62
Viral load
≤50 cop. ARN/mL 93 (92.1%)
>50 cop. ARN/mL 8 (7.9%)
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2.2. Variables
Chemsex practices were evaluated through an ad hoc questionnaire developed for this
study. The questionnaire included questions regarding the participants’ Chemsex practices
and their frequency during the last year, individuals with whom the participants engaged
in Chemsex (stable sexual partner, occasional sexual partner and/or both), the type and
the frequency of drugs consumed, and the time at which sex developed into Chemsex (e.g.,
whether drugs were taken before sex, during sex or before and during sex). The assessment of
other sexual practices included questions regarding the frequency of specific sexual practices
(double receptive anal penetration, double insertive anal penetration, receptive anal penetra-
tion, insertive anal penetration, fist penetration (fisting), anilingus, oral sex (fellatio) or mutual
masturbation), and condom use (frequency of condom use, condom use during the last anal
penetration or condomless anal intercourse at least once). These questions were answered by
participants separately regarding stable and occasional sexual partners.
Sexually transmitted diseases (STDs). A single question was included to evaluate if
participants were diagnosed with any of the following STDs at least once: genital warts,
genital ulcers, urethritis, proctitis, syphilis, chlamydia, candidiasis or gonorrhea.
Health-Related Quality of Life (HRQoL). For the evaluation of HRQoL, we employed
the Spanish version of the Medical Outcome Study-HIV Health Survey [44]. This ques-
tionnaire includes 11 subscales of HRQoL: General Health Perceptions (5 items), Pain (2
items), Physical Functioning (6 items), Role Functioning (2 items), Social Functioning (1
item), Mental Health (5 items), Energy/Fatigue (4 items), Cognitive Functioning (4 items),
Health Distress (4 items), Quality of Life (1 item) and Health Transition (1 item). The
scores obtained for these subscales can be quantified through the calculation of two general
indexes: Physical Health Summary (PHS) and Mental Health Summary (MHS). Questions
refer to the last two weeks and are rated on 2, 3, 5, and 6-point scales with a final score
reflected on a scale from 0 to 100. Higher scores indicate greater health [45]. A recent
reliability generalization meta-analysis pointed out that this instrument is highly reliable
for the evaluation of HRQoL, with an average α coefficient for the total score of MOS-HIV
of 0.91 and above 0.80 for all of the subscales, except for Role Functioning [46].
2.3. Procedure
The research was conducted in the Infectious Diseases Unit of the General University
Hospital of Alicante in Spain. All patients in usual care between February 2020 and
December 2020 who met the inclusion criteria were invited to participate in the study by
filling in the indicated self-reported questionnaires. The confidentiality and anonymity
of the obtained results was assured to participants throughout the whole study. Hence,
to protect the confidentiality and anonymity of the data, codes were assigned to identify
the participants. Furthermore, the research was conducted following the guidelines of the
Declaration of Helsinki and the European Union Good Clinical Practice Standards, and the
study was approved (26 February 2020) by the Ethics Committee of the General University
Hospital of Alicante (PI2019/083). Inclusion criteria were: (1) HIV infection diagnosis,
(2) ≥18 years-old, (3) being men who have sex with men, (4) being a patient receiving
antiretroviral therapy and (5) having signed the informed consent to participate in the
study. Exclusion criteria included: (1) the presence of comorbidities identified in medical
records, dementia or other central nervous system diseases, mental health condition(s)
diagnosis, viral chronic hepatitis, active cancer or infection, diabetes mellitus, high blood
pressure, cardiovascular disease, hypothyroidism, malnutrition and other severe health
conditions; (2) mental or physical impairments that could hinder participants’ ability to
complete or understand the study questionnaires. After potential participants signed
the informed consent, researchers exhaustively revised their medical records in order to
identify any of the previously indicated exclusion criteria. Compliance with any of these
exclusion criteria by patients led to exclusion from participation in the study. Participants
were retained in the final sample only if they responded to all the questions involving the
dependent variables.
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2.4. Data Analysis
Descriptive analyses of the sociodemographic characteristics of the sample were
carried out. The frequencies of characteristics of Chemsex and other sexual practices
were calculated. Differences between participants who practiced Chemsex and those who
did not in terms of STD diagnosis and condom use were analyzed by employing the
chi-square statistic. Differences in the frequency of sexual practices and HRQoL between
individuals who practice and do not practice Chemsex were identified through T-test
analyses. Moreover, specific differences between Chemsex practitioners, depending on
the time of the practice (e.g., whether drugs were taken before sex, during sex or before
and during sex), were evaluated by employing non-parametric analyses in the form of the
Kruskal–Wallis test. p < 0.05 was considered significant in all cases. All statistical analyses
were conducted using SPSS version 24.0 (Armonk, NY, USA).
3. Results
3.1. Characteristics of Chemsex Practice in the Sample
Forty-one (40.6%) participants indicated that they participated in Chemsex during
the last year and 60 (59.4%) indicated that they did not. Of these 41 participants, 8 (19.5%)
had a stable partner, 19 (46.3%) had occasional sexual partners and 14 (34.2%) had both.
With regard to the frequency of Chemsex, 20 (48.8%) participated in this sexual practice
rarely, 15 (36.6%) sometimes, 5 (12.2%) very often and 1 (2.4%) always or almost always.
Concerning the time at which participants consumed substances related to sexual practices,
10 (24.4%) consumed them before sex, 13 (31.6%) during sex and 18 (44%) before and
during sexual practices. Tables 2 and 3 include information regarding the time at which
participants consumed each type of substance (never, before, during or before and during
sexual practices) and the frequency of consumption of each type of substance.
Table 2. Type of drug consumed and time of drug consumption in relation to sex.
Time of Consumption
Drug Never Yes, Before Sex Yes, during Sex Yes, Before andduring Sex
LSD (Lysergic acid
diethylamide) 41 (100%) 0 (0%) 0 (0%) 0 (0%)
Hallucinogenic
Fungus 41 (100%) 0 (0%) 0 (0%) 0 (0%)
Anabolic steroid 41 (100%) 0 (0%) 0 (0%) 0 (0%)
Cannabis 25 (60.9%) 7 (17%) 3 (7.4%) 6 (14.7%)
Cocaine 26 (63.5%) 4 (9.7%) 6 (14.7%) 5 (12.1%)
Crack 41 (100%) 0 (0%) 0 (0%) 0 (0%)
Codeine 40 (97.6%) 0 (0%) 0 (0%) 1 (2.4%)









30 (73.1%) 2 (4.9%) 5 (12.2%) 4 (9.8%)
Heroin 41 (100%) 0 (0%) 0 (0%) 0 (0%)
Ketamine 39 (95.1%) 0 (0%) 0 (0%) 2 (4.9%)
Khat 40 (97.6%) 1 (2.4%) 0 (0%) 0 (0%)
Mephedrone 35 (85.3%) 1 (2.4%) 2 (5%) 3 (7.3%)
Morphine 41 (100%) 0 (0%) 0 (0%) 0 (0%)
Opium 40 (97.6%) 0 (0%) 0 (0%) 1 (2.4%)
Poppers 23 (56.1%) 2 (4.9%) 12 (29.3%) 4 (9.7%)
Amphetamine 29 (70.7%) 6 (14.7%) 2 (4.9%) 4 (9.7%)
Sildenafil 22 (53.7%) 14 (34.2%) 1 (2.4%) 4 (9.7%)
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Table 3. Frequency of type of drug consumed.
Frequency





diethylamide) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Hallucinogenic
Fungus 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Anabolic steroid 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Cannabis 0 (0%) 3 (18.8%) 4 (25%) 4 (25%) 5 (31.2%)
Cocaine 1 (6.7%) 8 (53.3%) 5 (33.3%) 0 (0%) 1 (6.7%)
Crack 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Codeine 1 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)











0 (0%) 5 (45.4%) 3 (27.3%) 3 (27.3%) 0 (0%)
Heroin 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Ketamine 0 (0%) 2 (100%) 0 (0%) 0 (0%) 0 (0%)
Khat 1 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Mephedrone 0 (0%) 5 (83.3%) 1 (16.7%) 0 (0%) 0 (0%)
Morphine 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Opium 0 (0%) 1 (100%) 0 (0%) 0 (0%) 0 (0%)
Poppers 3 (16.6%) 5 (27.7%) 7 (38.9%) 1 (5.55%) 2 (11.1%)
Amphetamine 1 (8.3%) 6 (50%) 3 (25%) 1 (8.3%) 1 (8.3%)
Sildenafil 4 (21%) 3 (15.9%) 5 (26.3%) 5 (26.3%) 2 (10.5%)
3.2. Sexual Practices of Participants with Stable Sexual Partners (n = 59) and Differences Based on
Chemsex Practice
In the case of participants with stable sexual partners, 25 (42.4%) practiced Chemsex
with their stable sexual partners and 34 (57.6%) did not. No differences were found between
groups of Chemsex practitioners in terms of the frequency of any of the sexual practices
evaluated with stable sexual partners (p > 0.05) (Figure 1).
3.3. Sexual Practices of Participants with Occasional Sexual Partners (n = 68) and Differences
Based on Chemsex Practice
For participants with occasional sexual partners, 33 (48.5%) practiced Chemsex with
occasional sexual partners and 35 (51.5%) did not. In this case, significant differences were
found for double receptive anal penetration t (36.991) = −2.445, p = 0.019, d = 0.80; double
insertive anal penetration t(37.226) = −2.498, p = 0.017, d = 0.81; insertive anal penetration
t(66) = −2.992, p = 0.004, d = 0.73; anilingus t(66) = −2.821, p = 0.006, d = 0.69; and oral
sex t(59.053) = −2.403, p = 0.019, d = 0.62. In all cases, those participants who practiced
Chemsex exhibited a higher frequency of the development of these sexual practices with
occasional sexual partners (Figure 2).
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3.4. Differences in Condom Use between Participants Who Practiced Chemsex and Those Who Did
Not
Regarding the frequency of condom use, differences were found in its employment
with occasional sexual partners between participants who practiced Chemsex and those
who did not (t (43.607) = 3.053, p = 0.004, d = 0.92). In this case, participants who practiced
Chemsex employed condoms with a lesser frequency with occasional sexual partners in
comparison to their counterparts who did not practice Chemsex. No differences were
found in the case of condom use with stable sexual partners (p > 0.05) (Figure 3).
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Yes 55 (80.9%) 23 (69.7%) 32 (91.4%)
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Regarding condomless anal intercourse at least once with stable and occasional sexual
partners of discordant/unknown serological status, participants who practiced Chemsex
exhibited a higher frequency of this practice with stable sexual partners. No differences
were found regarding occasional sexual partners (Table 5).
3.5. Differences in Sexually Transmitted Diseases (STDs) between Participants Who Practiced
Chemsex and Those Who Did Not
In the case of STD diagnosis in the evaluated sample, differences were found in the
case of genital warts and urethritis. In both cases, participants who practiced Chemsex
exhibited a higher prevalence of diagnosis of these diseases compared to their counterparts
who did not practice Chemsex (Table 6).
J. Clin. Med. 2021, 10, 1662 9 of 16
Table 5. Condomless anal intercourse at least once with stable and occasional sexual partners of
discordant/unknown serological status.
Condomless Anal Intercourse at Least Once






n = 34 χ2 p
Yes 10 (16.9%) 9 (36%) 1 (2.9%)
11.185 0.001No 49 (83.1%) 16 (64%) 33 (97.1%)






n = 35 χ2 p
Yes 18 (26.5%) 11 (33.3%) 7 (20%)
1.551 0.213No 50 (73.5%) 22 (66.7%) 28 (80%)
Table 6. Prevalence of STD diagnosis for all participants and for practitioners and non-practitioners
of Chemsex.
Total Chemsexn = 41
No Chemsex
n = 60 χ2 p
Genital
warts
Yes 27 (%) 16 (39%) 11 (18.3%)
5.324 0.021No 74 (%) 25 (61%) 49 (81.7%)
Genital
ulcers
Yes 1 (%) 1 (2.4%) 0 (0%)
1.478 0.224No 100 (%) 40 (97.6%) 60 (100%)
Urethritis
Yes 6 (%) 6 (14.6%) 0 (0%)
9.335 0.002No 95 (%) 35 (85.4%) 60 (100%)
Proctitis
Yes 0 (%) 0 (0%) 0 (0%) - -
No 101 (%) 41 (100%) 60 (100%)
Syphilis Yes 41 (%) 21 (51.2%) 20 (33.3%) 3.231 0.072No 60 (%) 20 (48.8%) 40 (66.7%)
Chlamydia Yes 11 (%) 6 (14.6%) 5 (8.3%) 0.996 0.318No 90 (%) 35 (85.4%) 55 (91.7%)
Candidiasis
Yes 6 (%) 4 (9.8%) 2 (3.3%)
1.798 0.180No 95 (%) 37 (90.2%) 58 (96.7%)
Gonorrhea
Yes 25 (%) 12 (29.3%) 13 (21.7%)
0.756 0.385No 76 (%) 29 (70.7%) 47 (78.3%)
3.6. Differences between Participants Who Practiced Chemsex and Those Who Did Not in Terms of
HRQoL
Differences in HRQoL between participants based on Chemsex practice were assessed.
As can be observed in Table 7, significant differences were identified in the following
domains: General Health Perception, Pain, Energy/Fatigue, Mental Health, Cognitive
Functioning, Physical Health Summary and Mental Health Summary. In all cases, partici-
pants who practiced Chemsex obtained lower scores in these dimensions, indicating a poor
HRQoL.
3.7. Differences in HRQoL Depending on the Moment of the Practice of Chemsex Regarding Sex
The Kruskal–Wallis test was conducted to examine the differences in HRQoL accord-
ing to the point at which sex became Chemsex (e.g., whether drugs were taken before
sex, during sex or before and during sex). Significant differences were found in terms of
Energy/Fatigue, Cognitive Functioning and Mental Health Summary. Post-hoc analyses
were conducted, adjusting for significance (Bonferroni adjustment). In the case of En-
ergy/Fatigue, no significant differences were found between specific groups. For Cognitive
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Functioning, significant differences were found between groups of participants who took
drugs before sex and those who took drugs before and during sex (p = 0.004). Similarly,
significant differences were found between the same groups in terms of their Mental Health
Summary (p = 0.023). In both cases, participants who took drugs before and during sex
presented lower scores in these dimensions of HRQoL in comparison to those who only
took drugs before sex (Table 8).
Table 7. Differences in Health-Related Quality of Life (HRQoL) between participants who practiced




n = 60 t p Effect Size
General Health
Perception 56.09 ± 24.14 68.75 ± 20.98 t(99) = 2.798 0.006 d = 0.56
Pain 65.85 ± 24.01 77.96 ± 21.88 t (99) = 2.625 0.010 d = 0.52
Physical Functioning 87.60 ± 17.88 91.38 ± 13.54 t (99) = 1.210 0.229 d = 0.24
Role Functioning 96.34 ± 17.28 97.50 ± 34.96 t (99) = 0.196 0.845 d = 0.03
Social Functioning 84.87 ± 23.57 91.33 ± 17.41 t (68.905) = 1.497 0.139 d = 0.36
Energy Fatigue 63.53 ± 19.50 74 ± 15.88 t (99) = 2.961 0.004 d = 0.59
Mental Health 64 ± 19.73 71.73 ± 16.43 t (99) = 2.139 0.035 d = 0.42
Health Distress 78.65 ± 26.29 87.91 ± 16.52 t (61.477) = 2.001 0.050 d = 0.51
Cognitive
Functioning 74.51 ± 21.47 84.25 ± 14.01 t (99) = 2.759 0.007 d = 0.55
Quality of Life 62.19 ± 21.73 68.75 ± 17.60 t (99) = 1.669 0.098 d = 0.33
Health Transition 59.75 ± 24.92 60.41 ± 17.40 t (66.112) = 0.147 0.884 d = 0.03
Physical Health
Summary 68.43 ± 16.85 78.01 ± 13.58 t (99) = 3.153 0.002 d = 0.63
Mental Health
Summary 69.47 ± 18.36 78.55 ± 12.34 t (64.343) = 2.769 0.007 d = 0.69











Mean rank Mean rank Mean rank H (df) p
General Health Perception 25.80 21.96 17.64 3.125 (2) 0.210
Pain 26.80 18.42 19.64 3.261 (2) 0.196
Physical Functioning 24.70 20.27 19.47 1.480 (2) 0.477
Role Functioning 22 18.85 22 4.415 (2) 0.110
Social Functioning 26.95 20.81 17.83 5.037 (2) 0.081
Energy Fatigue 29.20 17.23 19.17 6.459 (2) 0.040
Mental Health 28.55 19.08 18.19 5.322 (2) 0.070
Health Distress 25.75 20.77 18.53 2.448 (2) 0.294
Cognitive Functioning 30.55 21.46 15.36 10.478 (2) 0.005
Quality of Life 26.65 21.65 17.39 4.472 (2) 0.107
Health Transition 22.90 21.77 19.39 0.756 (2) 0.685
Physical Health Summary 28.60 19.73 17.69 5.548 (2) 0.062
Mental Health Summary 29.80 19.46 17.22 7.412 (2) 0.025
df (degrees of freedom).
4. Discussion
The present study provides new findings about the Chemsex phenomenon in Spanish
HIV-infected MSM. The prevalence of Chemsex practice was high between HIV-infected
MSM who attended our HIV clinic, taking into account that almost half of the participants
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(40.6%) in the study had practiced Chemsex at least once during the last year. Engagement
in this practice occurred with occasional sexual partners (46.3%), occasional and stable
partners (34.2%) and, in a lesser proportion, within stable couples (19.5%). Our results are
in accordance with published data from other European countries. In a review of scientific
and national surveillance from the United Kingdom, the authors reported a prevalence of
17% in non-HIV MSM attending sexual health clinics and 31% in HIV-infected MSM [17].
The Antiretrovirals, Sexual Transmission Risk and Attitudes (ASTRA) study, which re-
cruited HIV participants aged 18 years or older from eight HIV outpatient clinics, reported
a 51% prevalence of Chemsex practices in a sample of 2248 patients [47]. A Spanish study
from Madrid in HIV-positive people reported that 29.1% of the sample were Chemsex prac-
titioners [48]. These results show a high prevalence of sexualized drug use in HIV-infected
MSM, even higher than in HIV-negative people [17]. Different authors have explored
several reasons for Chemsex engagement. Lafortune et al. reported that Chemsex play a
role as a coping mechanism that helps individuals to deal with painful emotions or stressful
events [49]. Ahmed et al. identified romantic breakups, receiving an HIV diagnosis, the
death of a relative, and the accumulation of professional or domestic pressures as triggers
of Chemsex practice [50]. In this regard, unpleasant or painful emotional states, such
as loneliness [51,52], boredom [51], anxiety [53,54], depression [22], sleep problems [55],
stigma associated with HIV-positive status [56], feelings of rejection [57,58] and negative
body image [58], are more common among Chemsex users. Another reason why people
engage in Chemsex is the perception of lower sexual self-efficacy and sexual pain when
using drugs during sex. In fact, it has been found that sexual dysfunction and pain are
more prevalent among Chemsex users than non-users [59]. As such, Chemsex practitioners
use Chemsex to help themselves feel more attractive and to increase their sexual confidence,
pleasure, physical sensations and/or orgasm intensity [57,58]. In this regard, suffering
painful emotions, stressful events and psychological problems [60], as well as lower sexual
self-efficacy and sexual pain [61], have been previously described as significant predictors
of a low HRQoL in PLWHIV. Chemsex could be used as a coping mechanism to deal with
distressing emotions such as anxiety, loneliness, boredom, or feelings of rejection, among
others [51]. At the same time, this practice could be used to increase self-esteem, emotional
closeness and feelings of attractiveness when Chemsex practitioners are struggling with
sexual problems [58].
The most common Chemsex drugs used by participants in our study were cannabis,
cocaine, methamphetamine, MDMA (Methylene dioxymethamphetamine), GHB (Gamma
hydroxybutyrate)/GBL (Gamma butyrolactone), mephedrone, poppers, amphetamines
and sildenafil. Cannabis, amphetamines and sildenafil were more frequently used before
sex was initiated. This consumption pattern has been reported previously [19]. One
of the most commonly used drugs is sildenafil. In general, it is employed by people
without sexual problems, such as erectile dysfunction, probably due to the belief that
these drugs can increase libido and improve sexual performance, helping to sustain long-
lasting sexual activity and reverse the impotence-inducing effects of other substances (e.g.,
cocaine) or antiretroviral therapy [62]. During sex, participants used cocaine, GHB and
poppers more often. GHB is a potent central nervous system depressant and, alongside
poppers, can increase the libido, facilitating muscle relaxation to facilitate anal penetration
and decrease pain perception [63,64]. Cocaine is probably used to compensate for the
depressive symptoms caused by GHB and poppers, thereby increasing stimulation during
sex [40]. Methamphetamine, cocaine, MDMA, GHB, ketamine and mephedrone were
consumed both before and during sex, probably with the aim of enhancing, disinhibiting
or facilitating the sexual experience [17].
Our study shows that Chemsex users have a high risk of transmission of other STDs.
In this sense, it has been found that Chemsex practitioners with occasional sexual partners
had more condomless sex with partners with discordant or unknown HIV serological status
in comparison to non-practitioners. These results are supported by the literature, which
has described the relationship between Chemsex practice and a higher number of sexual
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partners, a higher frequency of condomless sex, and a higher frequency of risky sexual
behavior with partners of unknown or HIV-negative status while having a detectable viral
load [22,58,65]. In this regard, it has been identified that the use of condoms by many is
perceived as a reminder of their HIV status, interfering with their sexual pleasure, while
drug use is perceived as a means to achieve a release and to escape from the burdens of
HIV stigma [56]. Furthermore, Chemsex practitioners performed higher levels of risky
sexual practices with occasional sexual partners, such as double receptive anal penetration,
double insertive anal penetration and insertive anal penetration, which puts them at a
higher risk of STD transmission [58,65–67]. Hence, our results point out the high incidence
of STDs in HIV-positive MSM who practice Chemsex. Syphilis, gonorrhea and genital
warts were the most frequent STDs in all participants, but only genital warts and urethritis
of any origin were significantly more frequent in Chemsex users. In a UK study, authors
found similar results in a sample of 1734 participants that used drugs during sex, reporting
an increase in the incidence of new diagnoses of HIV infection, acute bacterial Sexually
Transmitted Infections (STIs), rectal STIs and hepatitis C [68]. These results highlight the
negative consequences of Chemsex on the health of this population.
In this sense, we analyzed the relationship between Chemsex and HRQoL in our
sample. Chemsex users obtained lower scores in the domains of General Health Perception,
Pain, Energy/Fatigue, Mental Health, Cognitive Functioning, Physical Health Summary
and Mental Health Summary. To the best of our knowledge, this is the first study that has
analyzed the specific association between Chemsex and HRQoL, employing specific evalu-
ation instruments for the analysis of this health marker in PLWHIV. Moreover, our study
points out that those who engage in more extreme forms of Chemsex, i.e., they take drugs
both before and during sex, in comparison to those who only take drugs before or during
sex, presented lower HRQoL scores, especially regarding Energy/Fatigue and Cognitive
Functioning. This is probably related to the fact that a higher frequency of consumption
and a larger quantity of drugs consumed could entail a significant deterioration of HRQoL.
Taking into account that HIV infection decreases HRQoL [69,70], and also that drug use,
such as methamphetamine [71] and recreational cannabis use [72] (among others [73]),
affect HRQoL, it seems clear that Chemsex is an important cause of HRQoL decreases
in PLWHIV. It is likely that a mixed effect of higher risky sexual practices and drug con-
sumption could be a plausible mechanism to explain the obtained results. However, it is
necessary to conduct new studies to identify how Chemsex affects HRQoL.
Although the present study advances our comprehension of Chemsex and its conse-
quences in terms of HRQoL in men with HIV who have sex with men, some limitations
should be taken into account. The design of the study only allows us to measure the
association of the measures, meaning that we cannot establish any causality. Furthermore,
the questionnaire was self-reported by the participants, meaning that some of them may
not have been entirely truthful. Moreover, the number of HIV-positive people in the study
sample was small, but we were able to confirm our results due to the fact that the par-
ticipants were representative of MSM in the target population. Finally, the prevalence of
depression, which has been previously related to HRQoL impairment, was not evaluated
in this study.
5. Conclusions
In conclusion, our study highlights the high prevalence of Chemsex in MSM with an
HIV infection who are undergoing antiretroviral treatment. MSM with HIV who practice
Chemsex participate in more risky sexual practices and make less use of condoms with
occasional partners, which leads to a greater risk of STD infection. In this sense, Chemsex
is clearly related to a worse HRQoL. Detecting Chemsex practices could provide useful
information to clinicians in order to establish prevention and intervention strategies for
reducing health deterioration in this population. Future studies are necessary to analyze the
specific mechanisms that explain the HRQoL deterioration in MSM who practice Chemsex,
and to develop and evaluate the effectiveness of prevention and intervention programs
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oriented toward a reduction in Chemsex and HRQoL deterioration in MSM with an HIV
infection.
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